1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-3-(ethylamino)azetidine-3-carboxamide benzenesulfonate | 956246-95-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-3-(ethylamino)azetidine-3-carboxamide benzenesulfonate
• 英文别名: CE-178,253-26；CE-178,253 benzenesulfonate；benzenesulfonic acid;1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-(ethylamino)azetidine-3-carboxamide
• CAS: 956246-95-0
• 化学式: C₆H₆O₃S*C₂₄H₂₃Cl₂N₇O
• 分子量: 654.577
• InChiKey: PUVYOZFJBITEFT-UHFFFAOYSA-N

物化性质

• 熔点：
  256.2-259.6 °C
• 溶解度：
  DMSO: 10mg/mL (clear solution)

计算性质

• 辛醇/水分配系数(LogP)：
  4.66
• 重原子数：
  44
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  164
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  CE-178253 、 苯磺酸 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 24.0h， 以90%的产率得到1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-3-(ethylamino)azetidine-3-carboxamide benzenesulfonate
  参考文献：
  名称：

  Cannabinoid receptor ligands and uses thereof

  摘要：

  化合物的化学式（I），其作为大麻素受体配体并在治疗与动物体内大麻素受体介导相关疾病中的用途被描述在此。

  公开号：

  US20040157839A1

文献信息

• Development of two synthetic routes to CE-178,253, a CB1 antagonist for the treatment of obesity
  作者：Thomas A. Brandt、Stéphane Caron、David B. Damon、Joseph DiBrino、Arun Ghosh、David A. Griffith、Sandeep Kedia、John A. Ragan、Peter R. Rose、Brian C. Vanderplas、Lulin Wei

  DOI：10.1016/j.tet.2008.10.067

  日期：2009.4

  CE-178,253 benzenesulfonate (1) is a CB1 antagonist discovered by Pfizer medicinal chemists. Two syntheses Of this compound are described. The first, based on the discovery synthesis, involves assembly of an aryl-substituted pyrazolotriazine core onto which the second aryl moiety is installed by a Suzuki Coupling: this route has been scaled to provide up to 6 kg of API. A second. more convergent route is also described, which installs the pyrazolotriazine containing both aryl substituents by condensation of a bromoketone with a substituted thiosemicarbazide. This route has been demonstrated on laboratory scale and is viewed as the preferred bond-forming sequence. (C) 2008 Elsevier Ltd. All rights reserved.
• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc

  公开号：US20040157839A1

  公开（公告）日：2004-08-12

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  化合物的化学式（I），其作为大麻素受体配体并在治疗与动物体内大麻素受体介导相关疾病中的用途被描述在此。